SRR25617838
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.480
- GLYCOLYSIS+0.250
- PANCREAS_BETA_CELLS+0.210
- HEDGEHOG_SIGNALING+0.200
- KRAS_SIGNALING_DN+0.190
- SPERMATOGENESIS+0.140
- MYC_TARGETS_V1+0.130
- HYPOXIA+0.110
- E2F_TARGETS+0.100
- MYOGENESIS+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- INTERFERON_GAMMA_RESPONSE-0.520
- PROTEIN_SECRETION-0.460
- ANDROGEN_RESPONSE-0.420
- COMPLEMENT-0.420
- UV_RESPONSE_DN-0.420
- PI3K_AKT_MTOR_SIGNALING-0.400
- ALLOGRAFT_REJECTION-0.380
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.848 |
| 2 | TCGA-E2-A574-01A-11R-A29R-07 | — | E | 0.847 |
| 3 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.846 |
| 4 | AUR-AFR5-TTM1-A-1-1-R-A743-41 | — | E | 0.846 |
| 5 | 264656b8-d45c-4f5c-a431-366c566296fe | — | — | 0.845 |
| 6 | SRR15069607 | — | — | 0.841 |
| 7 | TCGA-B6-A402-01A-11R-A239-07 | — | E | 0.836 |
| 8 | SRR8518307 | — | D | 0.834 |
| 9 | SRR25617841 | — | E | 0.834 |
| 10 | SRR5088856 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.480 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |